The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, ...

Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...

Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and ...

With quarterly revenue up 54% from a year ago, Eli Lilly raised it guidance for the year, with the company now expecting revenue in the range of $63 billion to $63.5 billion ...